Nicholas (Nick) Augustinos has served on our Board since November 2009. Nick is the President & CEO of Aver, Inc. a company specializing in bundled payment and analytics solutions. Besides his role as President & CEO Nick serves on the Board of Directors of Aver, Inc. Prior to Aver, Inc., Nick was the Senior Vice President Health Information Services and Strategy at Cardinal Health. In January 2015, he was appointed to the Board of Directors of the California Health Care Foundation (CHCF). CHCF has as its mission to improve care for all Californians through innovations that improve quality, increase efficiency, and lower the cost of care. Prior to CHCF Nick served on the Board of Directors of the SCAN Foundation (June 2011 - December 2014), an organization dedicated to advancing the development of a sustainable continuum of quality care for seniors. Nick served on the Board of Directors of Audax Health, now Rally (March 2012 - February 2014), specializing in consumer engagement solutions. Rally is currently part of Optum, a UnitedHealth Group company. Nick brings 30 years of broad managerial, consulting and business development experience in the private and public sector. He has worked with a diverse range of leading healthcare delivery systems, healthcare insurers and government organizations globally.
Prior to Cardinal Health, Nick was the Senior Director for Global Healthcare Operations at Cisco Systems, leading the go to market strategy for healthcare focusing on public sector bringing business and technical expertise along with thought leadership towards in the areas of connected health, wellness and care delivery. Nick started his career at Cisco as the Senior Director for Global Healthcare Solutions of the Internet Business Solutions Group – the strategic consulting business unit of Cisco – he led among other initiatives the Cisco HealthPresence™ development, Cisco’s core care-at-a-distance platform.
Prior to Cisco, Nick was Partner and Senior Strategic Consulting Expert, Global Health Services, for CSC. Prior to joining CSC, he was Vice President, Care Data Exchange business unit for CareScience, leading product development and services in the clinical document sharing space. Nick was also Vice President for Healtheon/ WebMD, responsible for marketing and sales for the company’s products and services. Prior to that, he was with Deloitte Consulting and was instrumental in establishing the healthcare practice for Deloitte’s San Francisco office, managing numerous projects for payers, providers, and integrated delivery networks. He started his career in healthcare as Vice President, Administration, of CliniShare.
What is Nicholas Augustinos' net worth?
The estimated net worth of Nicholas Augustinos is at least $60,732.10 as of February 16th, 2021. Mr. Augustinos owns 806 shares of DexCom stock worth more than $60,732 as of November 21st. This net worth estimate does not reflect any other investments that Mr. Augustinos may own. Learn More about Nicholas Augustinos' net worth.
How do I contact Nicholas Augustinos?
Has Nicholas Augustinos been buying or selling shares of DexCom?
Nicholas Augustinos has not been actively trading shares of DexCom over the course of the past ninety days. Most recently, Nicholas Augustinos sold 2,500 shares of the business's stock in a transaction on Friday, October 29th. The shares were sold at an average price of $600.03, for a transaction totalling $1,500,075.00. Learn More on Nicholas Augustinos' trading history.
Who are DexCom's active insiders?
DexCom's insider roster includes Donald Abbey (EVP), Steven Altman (Director), Nicholas Augustinos (Director), Andrew Balo (Insider), Quentin Blackford (COO), Michael Brown (EVP), Richard Collins (Director), Matthew Dolan (SVP), Richard Doubleday (EVP), Paul Flynn (EVP), Mark Foletta (Director), Bridgette Heller (Director), Barbara Kahn (Director), Jacob Leach (EVP), Jeffrey Moy (EVP), Patrick Murphy (EVP), Steven Pacelli (Insider), Chad Patterson (EVP), Barry Regan (EVP), Kevin Sayer (CEO), Shelly Selvaraj (SVP), Sumi Shrishrimal (SVP), Jay Skyler (Director), Sadie Stern (EVP), and Jereme Sylvain (CAO). Learn More on DexCom's active insiders.
Are insiders buying or selling shares of DexCom?
During the last twelve months, insiders at the medical device company sold shares 28 times. They sold a total of 252,409 shares worth more than $33,128,636.21. The most recent insider tranaction occured on September, 9th when EVP Sadie Stern sold 426 shares worth more than $29,457.90. Insiders at DexCom own 0.3% of the company.
Learn More about insider trades at DexCom. Information on this page was last updated on 9/9/2024.
